PEAR Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
Wednesday, 03 January 2018 05:06
Jan. 3, 2018 13:00 UTC

PEAR Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)-- PEAR Therapeutics, the leader in prescription digital therapeutics, today announced that Corey McCann, M.D., Ph.D., President and CEO of PEAR Therapeutics, will present at the

Error. Page cannot be displayed. Please contact your service provider for more details. (13)

annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 5:00 pm PST at the Westin St. Francis in San Francisco.

PEAR Therapeutics is a privately-held prescription digital therapeutics company developing clinically-validated, FDA-cleared software applications to treat severe medical conditions.

About PEAR Therapeutics

PEAR Therapeutics is the

leader in FDA-cleared prescription digital therapeutics. The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. PEAR’s lead product, reSET®, is an FDA-cleared 12-week interval prescription therapeutic for Substance Use Disorder (SUD) to be used as an adjunct to standard, outpatient treatment. PEAR’s product development pipeline includes reSET-O™ for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (THRIVE™), combat posttraumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive disorder, and insomnia, for which PEAR intends to obtain FDA clearance. For more details, please see www.peartherapeutics.com.

Contacts

MacDougall Biomedical Communications
Karen Sharma or Stefanie Tuck, 781-235-3060
pear@macbiocom.com


Source: PEAR Therapeutics




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and
firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 
BMR:1